Sinovac Biotech, Ltd.: updates and filings

SVANASDAQHealthcare · Pharmaceutical Preparations

Price

$6.47

November 18, 2026Market cap $465M

What Ploutos Investor adds for Sinovac Biotech

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • A figure that did not match the numbers it is built from has been left out.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Jun 5, 2026 latest annual
  • Aug 17, 2026Current report (foreign company)
    Form6-K
  • Jul 15, 2026Current report (foreign company)
    Form6-K
  • Jun 15, 2026Current report (foreign company)
    Form6-K
  • Jun 5, 2026Current report (foreign company)
    Form6-K
  • Jun 5, 2026Annual report (foreign company)for the period to Dec 31, 2025
    Form20-F
  • May 29, 2026Current report (foreign company)
    Form6-K
  • May 21, 2026Current report (foreign company)
    Form6-K
  • May 8, 2026Current report (foreign company)
    Form6-K
  • May 7, 2026Current report (foreign company)
    Form6-K
  • Apr 30, 2026Notice that the annual report will be filed late
    FormNT 20-F
  • Apr 30, 2026Annual report (foreign company)for the period to Dec 31, 2024
    Form20-F
  • Jan 22, 2026Current report (foreign company)
    Form6-K
  • Jan 5, 2026Current report (foreign company)
    Form6-K
  • Dec 17, 2025Current report (foreign company)
    Form6-K
  • Dec 17, 2025Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Nov 20, 2025Current report (foreign company)
    Form6-K
  • Nov 5, 2025Current report (foreign company)
    Form6-K
  • Sep 12, 2025Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Aug 21, 2025Current report (foreign company)
    Form6-K
  • Jul 15, 2025Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Jul 14, 2025Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Jul 14, 2025Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Jul 11, 2025Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Jul 11, 2025Current report (foreign company)
    Form6-K
  • Jul 10, 2025Current report (foreign company)
    Form6-K

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jan 20, 2000.

The full analysis

What do Sinovac Biotech's filings show?

The filings are where every one of Sinovac Biotech's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.